- Home
- REVB vs SGLY Comparison
REVB vs SGLY Comparison
Compare REVB & SGLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- SGLY
- Stock Information
- Founded
- REVB 2020
- SGLY 2001
- Country
- REVB United States
- SGLY United States
- Employees
- REVB N/A
- SGLY N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- SGLY
- Sector
- REVB Health Care
- SGLY
- Exchange
- REVB Nasdaq
- SGLY Nasdaq
- Market Cap
- REVB 3.8M
- SGLY 4.1M
- IPO Year
- REVB N/A
- SGLY 2008
- Fundamental
- Price
- REVB $2.58
- SGLY $0.95
- Analyst Decision
- REVB
- SGLY
- Analyst Count
- REVB 0
- SGLY 0
- Target Price
- REVB N/A
- SGLY N/A
- AVG Volume (30 Days)
- REVB 164.5K
- SGLY 12.9K
- Earning Date
- REVB 08-08-2025
- SGLY 08-26-2025
- Dividend Yield
- REVB N/A
- SGLY N/A
- EPS Growth
- REVB N/A
- SGLY N/A
- EPS
- REVB N/A
- SGLY N/A
- Revenue
- REVB N/A
- SGLY $2,172,036.00
- Revenue This Year
- REVB N/A
- SGLY N/A
- Revenue Next Year
- REVB N/A
- SGLY N/A
- P/E Ratio
- REVB N/A
- SGLY N/A
- Revenue Growth
- REVB N/A
- SGLY N/A
- 52 Week Low
- REVB $2.11
- SGLY $0.54
- 52 Week High
- REVB $168.00
- SGLY $7.65
- Technical
- Relative Strength Index (RSI)
- REVB 45.75
- SGLY 43.10
- Support Level
- REVB $2.39
- SGLY $0.92
- Resistance Level
- REVB $2.70
- SGLY $1.00
- Average True Range (ATR)
- REVB 0.21
- SGLY 0.04
- MACD
- REVB 0.03
- SGLY -0.00
- Stochastic Oscillator
- REVB 51.61
- SGLY 23.08
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.